TipRanks
Maravai Lifesciences Holdings (MX:MRVI)
:MRVI
Mexico Market
MRVI
Maravai Lifesciences Holdings
RESEARCH TOOLSreports

Maravai Lifesciences Holdings (MRVI) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

MRVI Analyst Ratings

Moderate Buy
6Ratings
Moderate Buy
4 Buy
2 Hold
0 Sell
Based on 6 analysts giving stock ratings to
Maravai
Lifesciences Holdings
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

MRVI Stock 12 Month Forecast

Average Price Target

$147.28
▲(20.72% Upside)
Based on 6 Wall Street analysts offering 12 month price targets for Maravai Lifesciences Holdings in the last 3 months. The average price target is $147.28 with a high forecast of $168.32 and a low forecast of $121.56. The average price target represents a 20.72% change from the last price of $122.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"84":"$84","169":"$169","105.25":"$105.3","126.5":"$126.5","147.75":"$147.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":168.31868337,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$168.32</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":147.27884794874998,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$147.28</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":121.563493545,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$121.56</span>\n  </div></div>","useHTML":true}}],"tickPositions":[84,105.25,126.5,147.75,169],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,122,125.56297564384616,129.12595128769232,132.68892693153845,136.2519025753846,139.81487821923076,143.37785386307692,146.94082950692308,150.50380515076924,154.0667807946154,157.62975643846153,161.19273208230769,164.75570772615384,{"y":168.31868337,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,122,123.94452676528846,125.88905353057692,127.83358029586537,129.77810706115383,131.7226338264423,133.66716059173075,135.61168735701924,137.5562141223077,139.50074088759615,141.4452676528846,143.38979441817307,145.33432118346153,{"y":147.27884794874998,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,122,121.96642258038462,121.93284516076923,121.89926774115385,121.86569032153847,121.83211290192308,121.7985354823077,121.7649580626923,121.73138064307692,121.69780322346153,121.66422580384615,121.63064838423077,121.59707096461538,{"y":121.563493545,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":85,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$168.32Average Price Target$147.28Lowest Price Target$121.56
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TD Cowen Analyst forecast on MX:MRVI
Brendan Smith
TD Cowen
TD Cowen
$168.32
Buy
37.97%
Upside
Initiated
10/05/26
Maravai Lifesciences initiated with a Buy at TD CowenMaravai Lifesciences initiated with a Buy at TD Cowen
Craig-Hallum Analyst forecast on MX:MRVI
Matt Hewitt
Craig-Hallum
Craig-Hallum
―
Buy
―
Reiterated
09/15/26
Analysts Are Bullish on These Healthcare Stocks: Maravai Lifesciences Holdings (MRVI), Thermo Fisher (TMO)
UBS Analyst forecast on MX:MRVI
Unknown Analyst
UBS
Not Ranked
UBS
$46.76→$149.62
Hold
22.64%
Upside
Initiated
09/08/26
Maravai Lifesciences Holdings (MRVI) Receives a New Rating from UBS
Stifel Nicolaus Analyst forecast on MX:MRVI
Daniel Arias
Stifel Nicolaus
Stifel Nicolaus
$149.62
Buy
22.64%
Upside
Reiterated
08/11/26
Stifel Nicolaus Sticks to Their Buy Rating for Maravai Lifesciences Holdings (MRVI)
William Blair Analyst forecast on MX:MRVI
Matt Larew
William Blair
William Blair
―
Hold
―
Reiterated
08/07/26
Analysts Offer Insights on Healthcare Companies: AMN Healthcare Services (NYSE: AMN), Maravai Lifesciences Holdings (NASDAQ: MRVI) and Humana (NYSE: HUM)
Wells Fargo Analyst forecast on MX:MRVI
Evan Stampler
Wells Fargo
Wells Fargo
$102.86→$121.56
Buy
-0.36%
Downside
Reiterated
08/07/26
Wells Fargo Remains a Buy on Maravai Lifesciences Holdings (MRVI)
Guggenheim Analyst forecast on MX:MRVI
Subbu Nambi
Guggenheim
Guggenheim
―
Hold
―
Reiterated
05/11/26
Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (NASDAQ: HRMY), Maravai Lifesciences Holdings (NASDAQ: MRVI) and Alkermes (NASDAQ: ALKS)
Deutsche Bank Analyst forecast on MX:MRVI
Justin Bowers
Deutsche Bank
Deutsche Bank
$84.16→$112.21
Buy
-8.02%
Downside
Reiterated
05/08/26
Maravai Lifesciences price target raised to $6 from $4.50 at Deutsche BankMaravai Lifesciences price target raised to $6 from $4.50 at Deutsche Bank
Jefferies Analyst forecast on MX:MRVI
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$93.51
Buy
-23.35%
Downside
Reiterated
02/26/26
Jefferies Remains a Buy on Maravai Lifesciences Holdings (MRVI)
Robert W. Baird Analyst forecast on MX:MRVI
Catherine Ramsey Schulte
Robert W. Baird
Robert W. Baird
$37.4→$56.11
Hold
-54.01%
Downside
Reiterated
02/26/26
Maravai Lifesciences price target raised to $3 from $2 at BairdMaravai Lifesciences price target raised to $3 from $2 at Baird
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TD Cowen Analyst forecast on MX:MRVI
Brendan Smith
TD Cowen
TD Cowen
$168.32
Buy
37.97%
Upside
Initiated
10/05/26
Maravai Lifesciences initiated with a Buy at TD CowenMaravai Lifesciences initiated with a Buy at TD Cowen
Craig-Hallum Analyst forecast on MX:MRVI
Matt Hewitt
Craig-Hallum
Craig-Hallum
―
Buy
―
Reiterated
09/15/26
Analysts Are Bullish on These Healthcare Stocks: Maravai Lifesciences Holdings (MRVI), Thermo Fisher (TMO)
UBS Analyst forecast on MX:MRVI
Unknown Analyst
UBS
Not Ranked
UBS
$46.76→$149.62
Hold
22.64%
Upside
Initiated
09/08/26
Maravai Lifesciences Holdings (MRVI) Receives a New Rating from UBS
Stifel Nicolaus Analyst forecast on MX:MRVI
Daniel Arias
Stifel Nicolaus
Stifel Nicolaus
$149.62
Buy
22.64%
Upside
Reiterated
08/11/26
Stifel Nicolaus Sticks to Their Buy Rating for Maravai Lifesciences Holdings (MRVI)
William Blair Analyst forecast on MX:MRVI
Matt Larew
William Blair
William Blair
―
Hold
―
Reiterated
08/07/26
Analysts Offer Insights on Healthcare Companies: AMN Healthcare Services (NYSE: AMN), Maravai Lifesciences Holdings (NASDAQ: MRVI) and Humana (NYSE: HUM)
Wells Fargo Analyst forecast on MX:MRVI
Evan Stampler
Wells Fargo
Wells Fargo
$102.86→$121.56
Buy
-0.36%
Downside
Reiterated
08/07/26
Wells Fargo Remains a Buy on Maravai Lifesciences Holdings (MRVI)
Guggenheim Analyst forecast on MX:MRVI
Subbu Nambi
Guggenheim
Guggenheim
―
Hold
―
Reiterated
05/11/26
Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (NASDAQ: HRMY), Maravai Lifesciences Holdings (NASDAQ: MRVI) and Alkermes (NASDAQ: ALKS)
Deutsche Bank Analyst forecast on MX:MRVI
Justin Bowers
Deutsche Bank
Deutsche Bank
$84.16→$112.21
Buy
-8.02%
Downside
Reiterated
05/08/26
Maravai Lifesciences price target raised to $6 from $4.50 at Deutsche BankMaravai Lifesciences price target raised to $6 from $4.50 at Deutsche Bank
Jefferies Analyst forecast on MX:MRVI
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$93.51
Buy
-23.35%
Downside
Reiterated
02/26/26
Jefferies Remains a Buy on Maravai Lifesciences Holdings (MRVI)
Robert W. Baird Analyst forecast on MX:MRVI
Catherine Ramsey Schulte
Robert W. Baird
Robert W. Baird
$37.4→$56.11
Hold
-54.01%
Downside
Reiterated
02/26/26
Maravai Lifesciences price target raised to $3 from $2 at BairdMaravai Lifesciences price target raised to $3 from $2 at Baird
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AORTArtivion
MDWDMediwound
IMUXImmunic
RZLTRezolute
DFTXDefinium Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Maravai Lifesciences Holdings

3 Months
Daniel AriasStifel Nicolaus
Success Rate
11/20 ratings generated profit
55%
Average Return
+0.03%
Copying Daniel Arias's trades and holding each position for 3 Months would result in 55.00% of your transactions generating a profit, with an average return of +0.03% per trade.
1 Year
Matt HewittCraig-Hallum
Success Rate
12/19 ratings generated profit
63%
Average Return
+46.20%
Copying Matt Hewitt's trades and holding each position for 1 Year would result in 63.16% of your transactions generating a profit, with an average return of +46.20% per trade.
2 Years
Matt HewittCraig-Hallum
Success Rate
16/19 ratings generated profit
84%
Average Return
+89.55%
Copying Matt Hewitt's trades and holding each position for 2 Years would result in 84.21% of your transactions generating a profit, with an average return of +89.55% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MRVI Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
0
0
0
0
0
Buy
5
3
2
3
4
Hold
2
2
1
3
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
7
5
3
6
7
In the current month, MRVI has received 4 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. MRVI average Analyst price target in the past 3 months is 147.28.
Each month's total comprises the sum of three months' worth of ratings.

MRVI Financial Forecast

MRVI Earnings Forecast

Next quarter’s earnings estimate for MRVI is -$1.05 with a range of -$1.45 to -$0.75. The previous quarter’s EPS was -$0.38. MRVI beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year MRVI has Performed in-line its overall industry.
Next quarter’s earnings estimate for MRVI is -$1.05 with a range of -$1.45 to -$0.75. The previous quarter’s EPS was -$0.38. MRVI beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year MRVI has Performed in-line its overall industry.

MRVI Sales Forecast

Next quarter’s sales forecast for MRVI is $818.37M with a range of $795.84M to $852.92M. The previous quarter’s sales results were $966.43M. MRVI beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year MRVI has Performed in-line its overall industry.
Next quarter’s sales forecast for MRVI is $818.37M with a range of $795.84M to $852.92M. The previous quarter’s sales results were $966.43M. MRVI beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year MRVI has Performed in-line its overall industry.

MRVI Stock Forecast FAQ

What is MX:MRVI’s average 12-month price target, according to analysts?
Based on analyst ratings, Maravai Lifesciences Holdings’s 12-month average price target is 147.28.
    What is MX:MRVI’s upside potential, based on the analysts’ average price target?
    Maravai Lifesciences Holdings has 20.72% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Maravai Lifesciences Holdings a Buy, Sell or Hold?
          Maravai Lifesciences Holdings has a consensus rating of Moderate Buy, which is based on 4 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Maravai Lifesciences Holdings’s share price target?
            The average share price target for Maravai Lifesciences Holdings is 147.28. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $168.32 ,and the lowest forecast is $121.56. The average share price target represents 20.72% Increase from the current price of $122.
              What do analysts say about Maravai Lifesciences Holdings?
              Maravai Lifesciences Holdings’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of Maravai Lifesciences Holdings?
                To buy shares of MX:MRVI, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.